Skip to content

Licensed medicine · Prescription only

OrforglipronOral non-peptide GLP-1 receptor agonist

Orforglipron is a once-daily tablet from Eli Lilly, sold as Foundayo. It is the weight-loss pill most people mean when they search for a GLP-1 in tablet form, and it is no longer investigational: the MHRA authorised it on 10 August 2026 for weight management and for type 2 diabetes, the first regulator in Europe to do so, after the FDA approved it on 1 April 2026. Unlike every other GLP-1 treatment it is a small molecule rather than a peptide, which is what allows it to be swallowed at all, and unlike semaglutide tablets it is taken at any time of day with no fasting and no limit on water. It is a prescription-only medicine, supplied by a registered pharmacy after an assessment.

How it is supplied

Licensed, and prescription-only. The MHRA authorised orforglipron on 10 August 2026 for weight management in adults with a BMI of 30 or above, or 27 to under 30 with at least one weight-related condition, and separately for type 2 diabetes. The FDA approved it on 1 April 2026. In the EU the CHMP has issued a positive opinion for both indications. It is not available on the NHS, where access would follow a NICE appraisal, so in practice it is a private prescription: an assessment, a named prescriber, and supply from a registered pharmacy. Powders sold online as "research grade" orforglipron remain unlicensed medicines of unverified identity and strength, and now carry the added risk of imitating something a pharmacy can legitimately dispense.

At a glance

Developer
Eli Lilly
Targets
GLP-1
Administration
Once-daily tablet, any time of day, no food or water restriction
Stage
Licensed medicine
Reported
12.4% · 72 weeks
Prescription-only medicine

How Orforglipron differs

It is not a peptide. Peptide drugs are broken down in the digestive tract, which is why almost every GLP-1 treatment is an injection. A small molecule survives the stomach, and that single chemical fact is what removes the needle.

It also removes the ritual, which is the part that decides whether people keep taking a tablet. Semaglutide tablets have to be swallowed on an empty stomach after at least eight hours without food, with no more than half a glass of water, and nothing else to eat, drink or swallow for the next thirty minutes. Orforglipron has none of those conditions: any time of day, with or without food.

The weight loss is smaller than the injections deliver. The top dose in ATTAIN-1 produced a mean reduction of 12.4% over 72 weeks, against roughly 20% for tirzepatide over the same period in SURMOUNT-5. The choice between them is a choice between effect size and a treatment someone will actually continue.

Being a small molecule cuts both ways. Peptides have very few drug interactions because they are not metabolised like ordinary medicines; orforglipron is, so its dose is capped at 9 mg alongside a strong CYP3A4 inhibitor or an OATP1B inhibitor, and strong CYP3A4 inducers are to be avoided. That is a conversation about your other medicines that the injections do not require.

It is licensed for two things. The injections licensed for weight management are licensed for weight management alone; Foundayo also carries a type 2 diabetes indication, as monotherapy or combined with other diabetes treatments.

Clinical evidence

What the trials showed

ATTAIN-1

Mean weight reduction of 12.4% at 72 weeks

3,127 adults with obesity, or overweight plus at least one weight-related condition, and without type 2 diabetes. Mean baseline BMI 37.0. In the intention-to-treat population the three doses studied produced reductions of 7.8%, 9.3% and 12.4% against 0.9% on placebo; the difference from placebo at the top dose was 11.5% (95% CI 10.6 to 12.3).

ATTAIN-1

Four in five reached 5%, one in five reached 20%

At the top dose, 77.1% lost at least 5% of body weight, 59.6% at least 10%, 39.6% at least 15% and 20.1% at least 20%. The placebo figures were 22.1%, 8.6%, 3.6% and 1.6%. The 5% threshold matters because it is the number written into the licences as the point at which continuing is reviewed.

ATTAIN-1 prediabetes subgroup

91.3% returned to normal blood glucose

Among the 1,128 participants who had prediabetes at baseline, 91.3% at the top dose had reverted to normoglycaemia by week 72, against 42.4% on placebo. Systolic blood pressure fell by 6.14 mmHg against 0.78 mmHg.

ATTAIN-1 body composition sub-study

Mostly fat, but not only fat

A DEXA sub-study in 171 participants found the weight lost was predominantly total body fat, including visceral fat. It also found a statistically significant reduction in lean mass, which is the finding behind every piece of advice on this site about protein and resistance training during treatment.

What is known about tolerability

  • The common side effects are the ones the class is known for: nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain. An oral route does not soften them, because they come from the mechanism rather than the needle.
  • Drug interactions are a real consideration here in a way they are not for the injections. The maximum dose is 9 mg when taken with a strong CYP3A4 inhibitor or a clinical OATP1B inhibitor, and strong CYP3A4 inducers should be avoided altogether. Tell your prescriber everything you take, prescribed or not.
  • No dose adjustment is needed for age, body weight or kidney function, including end-stage renal disease. It is not recommended in severe liver impairment.
  • Safety and efficacy in under-18s have not been established and there are no data.
  • The doses used in the trials — 6 mg, 12 mg and 36 mg — are not the strengths that were licensed, which run from 0.8 mg to 17.2 mg. Trial doses and marketed doses are not interchangeable numbers, and a figure from one does not describe the other.

Availability

Licensed, and prescription-only. The MHRA authorised orforglipron on 10 August 2026 for weight management in adults with a BMI of 30 or above, or 27 to under 30 with at least one weight-related condition, and separately for type 2 diabetes. The FDA approved it on 1 April 2026. In the EU the CHMP has issued a positive opinion for both indications. It is not available on the NHS, where access would follow a NICE appraisal, so in practice it is a private prescription: an assessment, a named prescriber, and supply from a registered pharmacy. Powders sold online as "research grade" orforglipron remain unlicensed medicines of unverified identity and strength, and now carry the added risk of imitating something a pharmacy can legitimately dispense.

Orforglipron: Common questions

Can you buy orforglipron online?

Yes, but only in one lawful way: from a registered pharmacy, against a prescription, after a prescriber has assessed you. Orforglipron was authorised by the MHRA on 10 August 2026 as Foundayo, so it is a prescription-only medicine rather than an investigational compound — which means the same rules apply to it as to Mounjaro or Wegovy. A website that will sell it to you without an assessment is not a pharmacy, and what arrives cannot be verified.

Is there a weight loss pill instead of an injection?

There are now two licensed ones. Foundayo (orforglipron) is a once-daily tablet taken at any time of day with no food or water restrictions. Wegovy tablets (oral semaglutide) are a once-daily tablet taken on an empty stomach after at least eight hours without food, with up to half a glass of water, and nothing else for thirty minutes afterwards. Both are prescription-only, and both deliver less weight loss on average than the injections.

What is the difference between Foundayo and the Wegovy pill?

Three things. The molecule: orforglipron is a small molecule, oral semaglutide is a peptide in a formulation designed to survive the stomach. The routine: Foundayo has no timing, food or water rules, while semaglutide tablets require a fast and a thirty-minute wait. And the licence: Foundayo is licensed for weight management and for type 2 diabetes, semaglutide tablets for weight management. Which suits a given person is a clinical decision, and adherence usually matters more than a percentage point.

Is a tablet as effective as an injection?

On the published numbers, no. Orforglipron produced a mean 12.4% reduction at 72 weeks at the highest dose studied, and tirzepatide produced about 20% over the same period in a head-to-head trial against semaglutide. A tablet that is taken is worth more than an injection that is abandoned, which is why the comparison is not settled by the percentages alone.

Why are most weight loss treatments injections?

Because they are peptides, and peptides are broken down in the digestive tract before they can be absorbed. Injecting bypasses that. Orforglipron is a small molecule rather than a peptide, which is why it can be given as an ordinary tablet with no special conditions.

Is orforglipron available on the NHS?

Not at present. The MHRA authorises a medicine as safe and effective; whether the NHS funds it is a separate decision that follows a NICE appraisal. Until that concludes, access in the UK is through a private prescription.